Sort   by:  
 Page size 
The androgen receptor (AR) plays a key role in progression to incurable androgen-ablation resistant prostate cancer (PCA). We have identified three novel AR splice variants lacking the ligand binding domain (designated as AR3, AR4 and AR5) in hormone insensitive PCA cells. AR3, one of the major spl...
ORGANISM(S): Homo sapiens 
The spliced variant forms of androgen receptor (AR-Vs) have been identified recently in castration-resistant prostate cancer (CRPC) cell lines and clinical samples. Here we identified the cistrome and transcriptome landscape of AR-Vs in CRPC cell lines and determine the clinical significance of AR v...
ORGANISM(S): Homo sapiens 
In castration-resistant prostate cancer (CRPC), clinical response to androgen receptor (AR) antagonists is limited mainly due to AR-variants expression and restored AR signaling. The metabolite spermine is most abundant in prostate and it decreases as prostate cancer progresses, but its functions re...
2023-10-11 | MTBLS8034 | MetaboLights
The androgen receptor (AR) is a key driver of prostate cancer (PC), even in the state of castration-resistant PC (CRPC), and frequently even after treatment with second-line hormonal therapies such as abiraterone and enzalutamide. The persistence of AR activity via both ligand-dependent and ligand-i...
ORGANISM(S): Homo sapiens 
ARv7, the most prevalent androgen receptor (AR) variant in castration resistant prostate cancer (CRPC), lacks the AR ligand binding domain (LBD) making it resistant to LBD-targeting pharmacological inhibitors, such as enzalutamide. Identifying new prostate cancer therapeutic targets by defining key ...
ORGANISM(S): Homo sapiens (Human) 
2026-04-06 | PXD021462 | Pride
Background. Androgen receptor splice variant-7 (AR-V7) is a truncated form of the androgen receptor protein which lacks the ligand-binding domain, the target of enzalutamide and abiraterone, but remains constitutively active as a transcription factor. We hypothesized that detection of AR-V7 in circ...
ORGANISM(S): Homo sapiens 
Androgen receptor splice variant expression and prostate cancer recurrence after salvage therapy
Androgene Receptor (AR) splice variant ARv567es mediated transcriptome in LNCaP cells
Role of androgen receptor splice variant 7 (AR-v7) in prostate cancer resistance to 2nd generation androgen receptor signaling inhibitors
Purpose of the study was to identify unique transcriptomic changes mediated by Androgen Receptor (AR) splice variant ARv567es in LNCaP cells
ORGANISM(S): Homo sapiens 
2021-07-07 | GSE151429 | GEO
Sort   by:  
 Page size